Abstract
Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which is responsible for Coronavirus disease (COVID-19) has spread to 220 countries and has been found to be challenging. Many variants detected after Wuhan-Hu-1 reference which were able to develop the resistance against the neutralizing antibodies induced by vaccine and may cause false negative results in diagnostic tests targeting the S gene. The COVID-19 cases are increasing rapidly in India and the government authorized a new vaccine for restricted use in emergency situation. This review discusses about the efficacy, safety, and economical aspects of vaccines authorized in India. The rAd26-s & rAd5-s (Gamaleya Research Institute of Epidemiology and Microbiology) demonstrate high efficacy as well as safety, followed by BBV152 (Bharat Biotech) and AZD1222 (Oxford AstraZeneca); AZD1222 is more economical than other two.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
